National Institutes
of Health scientists have confirmed the concepts that vitamin C is
selectively toxic to cancer cells and that tumor-toxic levels of vitamin
C can be attained using intravenous administration. The article, published
in the September 12, 2005 issue of the Proceedings
of the National Academy of Sciences1 concluded, "These findings give plausibility
to intravenous ascorbic acid in cancer treatment."

Orthomolecular medical researchers, including Nobel laureate Linus Pauling,
have long recognized the great importance of vitamin C in fighting cancer.2
Scientists associated with the Bio-Communications Research Institute
(BRCI) in Wichita, Kansas have published 20 scientific articles on the
subject.3 BCRI researchers first reported in 1995 that vitamin C in sufficient
amounts is selectively toxic to tumor cells. The authors concluded that
tumor-toxic levels of vitamin C could be achieved only by giving the
vitamin intravenously. Subsequent research from BCRI, published in the
British Journal of Cancer in 2001,4 was the first to describe in detail
the pharmacokinetics of high doses of intravenous vitamin C.

"It is gratifying to have our research on vitamin C and cancer confirmed
by scientists at the prestigious National Institutes of Health," said
Neil Riordan, Ph.D., BCRI's Research Director. "The findings
reinforce our goal and commitment to pursue cutting edge cancer research," added
Michael Gonzalez, Ph.D., D.Sc. of the University of Puerto Rico.

What is Orthomolecular Medicine?Linus Pauling defined orthomolecular
medicine as "the treatment
of disease by the provision of the optimum molecular environment, especially
the optimum concentrations of substances normally present in the human
body." Orthomolecular medicine uses safe, effective nutritional
therapy to fight illness. For more information: http://www.orthomolecular.org